Advisor Group Holdings, Inc. Altimmune, Inc. Transaction History

Advisor Group Holdings, Inc.

$42.2 Billion
Q3 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 15,115 shares of ALT stock, worth $121,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,115

Previous 3,270 362.23%

Holding current value

$121,675

Previous $21,000 338.1%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$5.5 - $8.1 $65,147 - $95,944	11,845 Added 362.23%	15,115 $92,000
Q2 2024 Aug 13, 2024	SELL	$5.91 - $10.23 $378,033 - $654,361	-63,965 Reduced 95.14%	3,270 $21,000
Q1 2024 May 10, 2024	BUY	$8.22 - $13.81 $202,565 - $340,319	24,643 Added 57.86%	67,235 $684,000
Q4 2023 Feb 12, 2024	BUY	$2.14 - $11.62 $83,783 - $454,934	39,151 Added 1137.78%	42,592 $479,000
Q3 2023 Nov 13, 2023	SELL	$2.4 - $3.45 $10,543 - $15,155	-4,393 Reduced 56.08%	3,441 $8,000
Q2 2023 Aug 10, 2023	BUY	$3.45 - $5.97 $11,785 - $20,393	3,416 Added 77.32%	7,834 $27,000
Q1 2023 May 12, 2023	SELL	$4.19 - $16.83 $2,090 - $8,398	-499 Reduced 10.15%	4,418 $18,000
Q4 2022 Feb 10, 2023	SELL	$8.74 - $16.45 $56,110 - $105,609	-6,420 Reduced 56.63%	4,917 $80,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $33,130 - $69,583	3,105 Added 37.72%	11,337 $145,000
Q2 2022 Aug 10, 2022	BUY	$3.94 - $11.77 $32,410 - $96,820	8,226 Added 137100.0%	8,232 $96,000
Q1 2022 May 04, 2022	SELL	$5.9 - $9.45 $13,003 - $20,827	-2,204 Reduced 99.73%	6 $0
Q3 2021 Nov 05, 2021	SELL	$8.43 - $16.81 $6,364 - $12,691	-755 Reduced 25.46%	2,210 $26,000
Q2 2021 Aug 02, 2021	SELL	$9.85 - $16.46 $87,645 - $146,461	-8,898 Reduced 75.01%	2,965 $29,000
Q1 2021 May 13, 2021	SELL	$12.71 - $24.31 $5,045 - $9,651	-397 Reduced 3.24%	11,863 $167,000
Q4 2020 Feb 10, 2021	BUY	$7.84 - $14.22 $41,230 - $74,782	5,259 Added 75.12%	12,260 $138,000
Q3 2020 Nov 12, 2020	SELL	$9.93 - $33.26 $2,015 - $6,751	-203 Reduced 2.82%	7,001 $92,000
Q2 2020 Aug 14, 2020	SELL	$2.9 - $10.71 $580 - $2,142	-200 Reduced 2.7%	7,204 $77,000
Q1 2020 May 18, 2020	BUY	$1.69 - $3.8 $12,512 - $28,135	7,404 New	7,404 $24,000

Others Institutions Holding ALT

# of Institutions

186

Shares Held

39.3M

Call Options Held

913K

Put Options Held

743K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $395M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Altimmune, Inc. Transaction History